Suppr超能文献

[成人哮喘急性加重相关问题]

[Adult asthma exacerbations in questions].

作者信息

Montani D, Cavailles A, Bertoletti L, Botelho A, Cortot A, Taillé C, Marchand-Adam S, Pinot D, Chouaid C, Crestani B, Garcia G, Humbert M, L'huillier J-P, Magnan A, Tillie-Leblond I, Chanez P

机构信息

Service de Pneumologie et de Réanimation Respiratoire, Hôpital Antoine-Béclère, Université Paris-Sud 11, AP-HP, 157 Rue de la Porte-de-Trivaux, 92140 Clamart, France.

出版信息

Rev Mal Respir. 2010 Dec;27(10):1175-94. doi: 10.1016/j.rmr.2010.10.005. Epub 2010 Nov 19.

Abstract

In this article a French working party critically review the international literature to revise the definition, pathophysiology, treatment and cost of exacerbations of adult asthma. The various guidelines do not always provide a consistent definition of exacerbations of asthma. An exacerbation can be defined as deterioration of clinical and/or functional parameters lasting more than 24 hours, without return to baseline, requiring a change of treatment. No single clinical or functional criterion can be used as an early marker of an exacerbation. Innate and acquired immune mechanisms, modified by contact with infectious, irritant or allergenic agents, participate in the pathogenesis of exacerbations, which are accompanied by bronchial inflammation. In 2010, mortality is related to progression of exacerbations, often occurring before the patient seeks medical attention. The objective of treatment is to control asthma and prevent exacerbations. However, many factors can trigger exacerbations and often cannot be controlled. The efficacy of inhaled corticosteroids has been demonstrated on reduction of the number of exacerbations and the number of asthma-related deaths. This treatment is cost-effective, especially in terms of reduction of exacerbations.

摘要

在本文中,一个法国工作小组严谨地审视了国际文献,以修订成人哮喘急性加重的定义、病理生理学、治疗方法及成本。各种指南对哮喘急性加重的定义并不总是一致的。急性加重可定义为临床和/或功能参数恶化持续超过24小时,未恢复至基线水平,且需要改变治疗方案。没有单一的临床或功能标准可作为急性加重的早期标志物。与感染性、刺激性或变应原性物质接触后发生改变的先天性和获得性免疫机制参与了伴有支气管炎症的急性加重的发病过程。2010年,死亡率与急性加重的进展相关,这常常发生在患者就医之前。治疗的目标是控制哮喘并预防急性加重。然而,许多因素可引发急性加重,且往往无法控制。吸入性糖皮质激素在减少急性加重次数和哮喘相关死亡人数方面的疗效已得到证实。这种治疗具有成本效益,尤其是在减少急性加重方面。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验